MAB10009
Anti-IDO Antibody, clone 1F8.2
clone 1F8.2, from mouse
Synonym(s):
Indoleamine-pyrrole 2,3-dioxygenase, indole 2,3-dioxygenase, indoleamine 2,3-dioxygenase 1, indoleamine-pyrrole 2,3 dioxygenase, IDO1
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
1F8.2, monoclonal
species reactivity
human
technique(s)
immunohistochemistry: suitable
western blot: suitable
isotype
IgG1κ
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... IDO1(3620)
General description
Indoleamine 2,3-dioxygenase (IDO) is an enzyme that is responsible for converting tryptophan to kynurenines. IDO is expressed by a wide variety of tissues and IDO can be upregulated by interferon gamma. IDO modulates levels of the amino acid tryptophan, which is vital for cell growth, but is also involved in the suppression of the immune response. IDO may be involved in the
suppression of the immune response to tumours and blocking the IDO pathway may be a potential target for immunotherapy.
suppression of the immune response to tumours and blocking the IDO pathway may be a potential target for immunotherapy.
Specificity
This antibody recognizes IDO.
Immunogen
GST-tagged recombinant protein of full-length human IDO.
Application
Anti-IDO Antibody, clone 1F8.2 is an antibody against IDO for use in WB, IH.
Research Category
Neuroscience
Neuroscience
Research Sub Category
Oxidative Stress
Oxidative Stress
Quality
Evaluated by Western Blot in HeLa cell lysate.
Western Blot Analysis: 0.1 µg/mL dilution of this antibody detected IDO on 15 µg of HeLa cell lysate.
Western Blot Analysis: 0.1 µg/mL dilution of this antibody detected IDO on 15 µg of HeLa cell lysate.
Target description
Approx. 45 kDa
Physical form
Format: Purified
Mouse monoclonal in buffer containing 0.1 M Tris-glycine, pH 7.4, 150 mM NaCl and 0.05% sodium azide.
Protein G Purified
Storage and Stability
Maintain refrigerated at 2-8°C for 1 year from date of receipt.
Analysis Note
Control
HeLa cell lysate treated with interferon gamma.
HeLa cell lysate treated with interferon gamma.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Tamara Vorobjova et al.
World journal of gastroenterology, 21(2), 439-452 (2015-01-17)
To investigate the densities of dendritic cells (DCs) and FOXP3(+) regulatory T cells (Tregs) and their interrelations in the small bowel mucosa in untreated celiac disease (CD) patients with and without type 1 diabetes (T1D). Seventy-four patients (45 female, 29
Asha M Rudjord-Levann et al.
iScience, 26(7), 106984-106984 (2023-08-03)
Galectins are a group of carbohydrate-binding proteins with a presumed immunomodulatory role and an elusive function on antigen-presenting cells. Here we analyzed the expression of galectin-1 and found upregulation of galectin-1 in the extracellular matrix across multiple tumors. Performing an
Lieke L van der Woude et al.
Journal for immunotherapy of cancer, 10(10) (2022-10-18)
Immunotherapy is currently part of the standard of care for patients with advanced-stage non-small cell lung cancer (NSCLC). However, many patients do not respond to this treatment, therefore combination strategies are being explored to increase clinical benefit. The PEMBRO-RT trial
Trine Zeeberg Iversen et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(1), 221-232 (2013-11-13)
To investigate targeting of indoleamine 2,3 dioxygenase (IDO) enzyme using a synthetic peptide vaccine administered to patients with metastatic non-small cell lung cancer (NSCLC). In a clinical phase I study, we treated 15 HLA-A2-positive patients with stage III-IV NSCLC in
Maria A Papadaki et al.
Cancers, 12(6) (2020-06-18)
The current study aimed at the optimization of circulating tumor cell (CTC) enrichment for downstream protein expression analyses in non-small cell lung cancer (NSCLC) to serve as a tool for the investigation of immune checkpoints in real time. Different enrichment
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service